• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

他莫昔芬在绝经前和绝经后乳腺癌女性中的药代动力学。

Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer.

作者信息

Lien E A, Anker G, Ueland P M

机构信息

Department of Clinical Biology, Haukeland University Hospital, Bergen, Norway.

出版信息

J Steroid Biochem Mol Biol. 1995 Nov;55(2):229-31. doi: 10.1016/0960-0760(95)00169-z.

DOI:10.1016/0960-0760(95)00169-z
PMID:7495702
Abstract

We measured the serum levels of tamoxifen and 5 of its metabolites in serum from 7 premenopausal and 9 postmenopausal women during the first 56 days of treatment. The serum levels of N-desdimethyltamoxifen were higher in postmenopausal women compared to premenopausal women (P < 0.02). A similar trend was observed for N-desmethyltamoxifen (P = 0.06).

摘要

我们测量了7名绝经前和9名绝经后女性在治疗的前56天血清中他莫昔芬及其5种代谢物的水平。绝经后女性血清中N-去甲基他莫昔芬的水平高于绝经前女性(P < 0.02)。N-去甲他莫昔芬也观察到类似趋势(P = 0.06)。

相似文献

1
Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer.他莫昔芬在绝经前和绝经后乳腺癌女性中的药代动力学。
J Steroid Biochem Mol Biol. 1995 Nov;55(2):229-31. doi: 10.1016/0960-0760(95)00169-z.
2
Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.有症状的他莫昔芬治疗组与未治疗的绝经前和绝经后乳腺癌患者子宫内膜变化的比较。
Gynecol Oncol. 1997 Aug;66(2):233-7. doi: 10.1006/gyno.1997.4739.
3
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.在稳态治疗期间,血清中他莫昔芬及其代谢物的浓度随年龄的增长而增加。
Breast Cancer Res Treat. 2013 Sep;141(2):243-8. doi: 10.1007/s10549-013-2677-9. Epub 2013 Sep 1.
4
The serum estradiol concentration is the main determinant of the estradiol concentration in normal breast tissue.血清雌二醇浓度是正常乳腺组织中雌二醇浓度的主要决定因素。
Maturitas. 2015 May;81(1):42-5. doi: 10.1016/j.maturitas.2015.01.014. Epub 2015 Feb 7.
5
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.接受激素治疗的乳腺癌女性的妇科服务利用情况。
Am J Obstet Gynecol. 2017 Jul;217(1):59.e1-59.e12. doi: 10.1016/j.ajog.2017.03.011. Epub 2017 Mar 21.
6
Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer.乳腺癌辅助激素治疗结束后绝经前和绝经后女性的骨折发生率
Breast. 2015 Apr;24(2):153-8. doi: 10.1016/j.breast.2014.12.008. Epub 2015 Jan 22.
7
Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients.衰老可能与乳腺癌患者体内他莫昔芬及其代谢物的浓度有关。
J Womens Health (Larchmt). 2003 Oct;12(8):799-808. doi: 10.1089/154099903322447765.
8
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.他莫昔芬代谢可预测绝经前早期乳腺癌患者的药物浓度及预后。
Pharmacogenomics J. 2015 Feb;15(1):84-94. doi: 10.1038/tpj.2014.34. Epub 2014 Aug 5.
9
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.绝经后乳腺癌妇女服用他莫昔芬稳态期间他莫昔芬、雌激素和 FSH 血清水平的相关性。
BMC Cancer. 2010 Jun 21;10:313. doi: 10.1186/1471-2407-10-313.
10
Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer.他莫昔芬对局部区域复发的绝经前乳腺癌女性可能产生的有害影响。
Eur J Cancer. 1996 Nov;32A(12):2173-6. doi: 10.1016/s0959-8049(96)00227-4.

引用本文的文献

1
Tamoxifen for adults with hepatocellular carcinoma.他莫昔芬治疗肝细胞癌成人患者。
Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014869. doi: 10.1002/14651858.CD014869.pub2.
2
Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.激素状态会影响接受他莫昔芬治疗的乳腺癌患者体内他莫昔芬及其主要代谢物的血浆暴露水平。
BMC Pharmacol Toxicol. 2019 Dec 19;20(Suppl 1):81. doi: 10.1186/s40360-019-0358-y.
3
Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
群体药代动力学建模以评估CYP2D6和CYP3A代谢表型对他莫昔芬和4-羟基他莫昔芬药代动力学的影响。
Br J Clin Pharmacol. 2014 Sep;78(3):572-86. doi: 10.1111/bcp.12388.
4
A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.左旋肉碱在乳腺癌治疗女性他莫昔芬副作用管理中的作用综述
Tumour Biol. 2014 Apr;35(4):2845-55. doi: 10.1007/s13277-013-1477-5. Epub 2013 Dec 12.
5
Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.不同CYP2D6表型女性中他莫昔芬及其代谢物的生理药代动力学建模为他莫昔芬质量平衡提供了新的见解。
Front Pharmacol. 2012 May 21;3:92. doi: 10.3389/fphar.2012.00092. eCollection 2012.
6
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.4-羟基-N-去甲他莫昔芬和他莫昔芬-N-氧化物的组织分布。
Breast Cancer Res Treat. 2012 Jul;134(2):693-700. doi: 10.1007/s10549-012-2074-9. Epub 2012 May 5.